Hawaii 2023 Regular Session

Hawaii Senate Bill SCR215 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	THE SENATE S.C.R. NO. 215 THIRTY-SECOND LEGISLATURE, 2023 STATE OF HAWAII SENATE CONCURRENT RESOLUTION Requesting The Department of Health to convene a Medicinal Psychedelics Right-to-Try Task Force to explore the development of a program FOR QUALIFYING terminally ill patients.
2	2
3	3	THE SENATE S.C.R. NO. 215
4	4	THIRTY-SECOND LEGISLATURE, 2023
5	5	STATE OF HAWAII
6	6
7	7	THE SENATE
8	8
9	9	S.C.R. NO.
10	10
11	11	215
12	12
13	13	THIRTY-SECOND LEGISLATURE, 2023
14	14
15	15
16	16
17	17	STATE OF HAWAII
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29	SENATE CONCURRENT
30	30
31	31	RESOLUTION
32	32
33	33
34	34
35	35
36	36
37	37	Requesting The Department of Health to convene a Medicinal Psychedelics Right-to-Try Task Force to explore the development of a program FOR QUALIFYING terminally ill patients.
38	38
39	39
40	40
41	41
42	42
43	43	WHEREAS, the United States Food and Drug Administration's (FDA) approval process for investigational drugs and biological products protects patients in the United States from premature, ineffective, and unsafe medications and treatments, however, the approval process takes many years from start to final approval; and WHEREAS, potentially beneficial treatments that have not been granted FDA approval can be unavailable to patients who have been diagnosed with a terminal illness thereby severely restricting their care options; and WHEREAS, recognizing that terminally ill patients often do not have the time to wait for a potentially lifesaving investigational drug or biological product to obtain final FDA approval, the federal government and forty-one states have enacted "Right-to-Try" legislation that makes available experimental drugs that have not obtained FDA approval to terminally ill patients with no other medication or treatment options; and WHEREAS, Hawaii has a shortage of mental health professionals and should actively consider nontraditional, innovative, and safe solutions to treat its residents; and WHEREAS, studies conducted by nationally and internationally recognized medical institutions indicate that psilocybin and psilocin have shown efficacy, tolerability, and safety in the treatment of a variety of mental health conditions, including addiction, depression, anxiety disorders, and end-of-life psychological distress; and WHEREAS, the FDA has determined that preliminary clinical evidence indicates that psilocybin and psilocin may demonstrate substantial improvement over available therapies for major depressive disorder and severe treatment-resistant depression and has designated psilocybin therapy a breakthrough therapy, which is meant to accelerate the typically sluggish process of drug development and review; and WHEREAS, it is essential for the Legislature to have information to make an informed decision as to whether the State should enact its own "Right-to-Try" legislation that grants qualifying terminally ill patients access to experimental psychedelic drugs, including psilocybin and psilocin, that have not received final approval from the FDA; now, therefore, BE IT RESOLVED by the Senate of the Thirty-second Legislature of the State of Hawaii, Regular Session of 2023, the House of Representatives concurring, that the Department of Health is requested to convene a Medicinal Psychedelics Right-to-Try Task Force to explore development of a program that grants qualifying terminally ill patients access to psychedelic drugs, including psilocybin and psilocin, prior to their receiving final approval from the FDA; and BE IT FURTHER RESOLVED that the Medicinal Psychedelics Right-to-Try Task Force is requested to examine various issues pertaining to allowing qualifying terminally ill patients access to non-FDA-approved psychedelic drugs, including: (1) Relevant federal and state laws and regulations; (2) The types of non-FDA-approved psychedelic drugs that may be offered to a qualifying terminally ill patient in this State, including psilocybin and psilocin; (3) Conditions under which a terminally ill patient may qualify to be granted access to the non-FDA-approved psychedelic drugs, including whether a prescription from a health care provider should be necessary; (4) Methods by which the non-FDA-approved psychedelic drugs may be distributed to a qualifying terminally ill patient in the State; (5) Costs of the non-FDA-approved psychedelic drugs to be incurred by the qualifying terminally ill patient; (6) Health insurance coverage for non-FDA-approved psychedelic drugs; and (7) Statutory protections that need to be granted to qualifying terminally ill patients who are granted access to non-FDA-approved psychedelic drugs and persons who engage or assist in providing qualifying terminally ill patients access to the non-FDA-approved psychedelic drugs, including health care providers, manufacturers, dispensaries, and persons who transport the drugs, if any; and BE IT FURTHER RESOLVED that the following individuals, or their respective designees, are requested to serve as members of the Medicinal Psychedelics Right-to-Try Task Force: (1) The Director of Health, who is requested to serve as chairperson of the task force; (2) The Attorney General; (3) Faculty members from the University of Hawaii System with relevant scientific expertise; (4) The chairpersons of the Senate and House of Representatives Standing Committees whose subject matter purviews include health and the Judiciary; (5) A clinical practitioner licensed to prescribe psychotropic medication in the State to be invited by the chairperson of the task force; (6) A representative of the Drug Policy Forum of Hawaii, to be invited by the chairperson of the task force; (7) A representative of the Clarity Project, to be invited by the chairperson of the task force; (8) A representative of the Hawaii Psychiatric Medical Association, to be invited by the chairperson of the task force; and (9) A representative of the public with psychedelics‑related industry experience, to be invited by the chairperson of the task force; and BE IT FURTHER RESOLVED that the chairperson of the Medicinal Psychedelics Right-to-Try Task Force may invite other interested parties with relevant experience to join the task force, provided that the task force does not exceed fifteen members; and BE IT FURTHER RESOLVED that the Medicinal Psychedelics Right-to-Try Task Force is requested to submit a preliminary report of its findings and recommendations to the Legislature no later than twenty days prior to the convening of the Regular Session of 2024, and a final report of its findings and recommendations, including any proposed legislation, to the Legislature no later than twenty days prior to the convening of the Regular Session of 2025; and BE IT FURTHER RESOLVED that the Medicinal Psychedelics Right-to-Try Task Force is requested to dissolve on July 1, 2025; and BE IT FURTHER RESOLVED that certified copies of this Concurrent Resolution be transmitted to the Director of Health, who in turn shall notify the non-governmental organizations represented in the working group; Attorney General; and President of the University of Hawaii. OFFERED BY: _____________________________ Report Title: Medicinal Psychedelics; Psilocybin; Psilocin; Right-to-Try; Task Force; Department of Health
44	44
45	45	WHEREAS, the United States Food and Drug Administration's (FDA) approval process for investigational drugs and biological products protects patients in the United States from premature, ineffective, and unsafe medications and treatments, however, the approval process takes many years from start to final approval; and
46	46
47	47
48	48
49	49	WHEREAS, potentially beneficial treatments that have not been granted FDA approval can be unavailable to patients who have been diagnosed with a terminal illness thereby severely restricting their care options; and
50	50
51	51
52	52
53	53	WHEREAS, recognizing that terminally ill patients often do not have the time to wait for a potentially lifesaving investigational drug or biological product to obtain final FDA approval, the federal government and forty-one states have enacted "Right-to-Try" legislation that makes available experimental drugs that have not obtained FDA approval to terminally ill patients with no other medication or treatment options; and
54	54
55	55
56	56
57	57	WHEREAS, Hawaii has a shortage of mental health professionals and should actively consider nontraditional, innovative, and safe solutions to treat its residents; and
58	58
59	59
60	60
61	61	WHEREAS, studies conducted by nationally and internationally recognized medical institutions indicate that psilocybin and psilocin have shown efficacy, tolerability, and safety in the treatment of a variety of mental health conditions, including addiction, depression, anxiety disorders, and end-of-life psychological distress; and
62	62
63	63
64	64
65	65	WHEREAS, the FDA has determined that preliminary clinical evidence indicates that psilocybin and psilocin may demonstrate substantial improvement over available therapies for major depressive disorder and severe treatment-resistant depression and has designated psilocybin therapy a breakthrough therapy, which is meant to accelerate the typically sluggish process of drug development and review; and
66	66
67	67
68	68
69	69	WHEREAS, it is essential for the Legislature to have information to make an informed decision as to whether the State should enact its own "Right-to-Try" legislation that grants qualifying terminally ill patients access to experimental psychedelic drugs, including psilocybin and psilocin, that have not received final approval from the FDA; now, therefore,
70	70
71	71
72	72
73	73	BE IT RESOLVED by the Senate of the Thirty-second Legislature of the State of Hawaii, Regular Session of 2023, the House of Representatives concurring, that the Department of Health is requested to convene a Medicinal Psychedelics Right-to-Try Task Force to explore development of a program that grants qualifying terminally ill patients access to psychedelic drugs, including psilocybin and psilocin, prior to their receiving final approval from the FDA; and
74	74
75	75
76	76
77	77	BE IT FURTHER RESOLVED that the Medicinal Psychedelics Right-to-Try Task Force is requested to examine various issues pertaining to allowing qualifying terminally ill patients access to non-FDA-approved psychedelic drugs, including:
78	78
79	79
80	80
81	81	(1) Relevant federal and state laws and regulations;
82	82
83	83
84	84
85	85	(2) The types of non-FDA-approved psychedelic drugs that may be offered to a qualifying terminally ill patient in this State, including psilocybin and psilocin;
86	86
87	87
88	88
89	89	(3) Conditions under which a terminally ill patient may qualify to be granted access to the non-FDA-approved psychedelic drugs, including whether a prescription from a health care provider should be necessary;
90	90
91	91
92	92
93	93	(4) Methods by which the non-FDA-approved psychedelic drugs may be distributed to a qualifying terminally ill patient in the State;
94	94
95	95
96	96
97	97	(5) Costs of the non-FDA-approved psychedelic drugs to be incurred by the qualifying terminally ill patient;
98	98
99	99
100	100
101	101	(6) Health insurance coverage for non-FDA-approved psychedelic drugs; and
102	102
103	103
104	104
105	105	(7) Statutory protections that need to be granted to qualifying terminally ill patients who are granted access to non-FDA-approved psychedelic drugs and persons who engage or assist in providing qualifying terminally ill patients access to the non-FDA-approved psychedelic drugs, including health care providers, manufacturers, dispensaries, and persons who transport the drugs, if any; and
106	106
107	107
108	108
109	109	BE IT FURTHER RESOLVED that the following individuals, or their respective designees, are requested to serve as members of the Medicinal Psychedelics Right-to-Try Task Force:
110	110
111	111
112	112
113	113	(1) The Director of Health, who is requested to serve as chairperson of the task force;
114	114
115	115
116	116
117	117	(2) The Attorney General;
118	118
119	119
120	120
121	121	(3) Faculty members from the University of Hawaii System with relevant scientific expertise;
122	122
123	123
124	124
125	125	(4) The chairpersons of the Senate and House of Representatives Standing Committees whose subject matter purviews include health and the Judiciary;
126	126
127	127
128	128
129	129	(5) A clinical practitioner licensed to prescribe psychotropic medication in the State to be invited by the chairperson of the task force;
130	130
131	131
132	132
133	133	(6) A representative of the Drug Policy Forum of Hawaii, to be invited by the chairperson of the task force;
134	134
135	135
136	136
137	137	(7) A representative of the Clarity Project, to be invited by the chairperson of the task force;
138	138
139	139
140	140
141	141	(8) A representative of the Hawaii Psychiatric Medical Association, to be invited by the chairperson of the task force; and
142	142
143	143
144	144
145	145	(9) A representative of the public with psychedelics‑related industry experience, to be invited by the chairperson of the task force; and
146	146
147	147
148	148
149	149	BE IT FURTHER RESOLVED that the chairperson of the Medicinal Psychedelics Right-to-Try Task Force may invite other interested parties with relevant experience to join the task force, provided that the task force does not exceed fifteen members; and
150	150
151	151
152	152
153	153	BE IT FURTHER RESOLVED that the Medicinal Psychedelics Right-to-Try Task Force is requested to submit a preliminary report of its findings and recommendations to the Legislature no later than twenty days prior to the convening of the Regular Session of 2024, and a final report of its findings and recommendations, including any proposed legislation, to the Legislature no later than twenty days prior to the convening of the Regular Session of 2025; and
154	154
155	155
156	156
157	157	BE IT FURTHER RESOLVED that the Medicinal Psychedelics Right-to-Try Task Force is requested to dissolve on July 1, 2025; and
158	158
159	159
160	160
161	161	BE IT FURTHER RESOLVED that certified copies of this Concurrent Resolution be transmitted to the Director of Health, who in turn shall notify the non-governmental organizations represented in the working group; Attorney General; and President of the University of Hawaii.
162	162
163	163
164	164
165	165
166	166
167	167
168	168
169	169	OFFERED BY: _____________________________
170	170
171	171
172	172
173	173	OFFERED BY:
174	174
175	175	_____________________________
176	176
177	177
178	178
179	179
180	180
181	181	Report Title:
182	182
183	183	Medicinal Psychedelics; Psilocybin; Psilocin; Right-to-Try; Task Force; Department of Health